All In Biotech

Drug Trial Radar · NCT07215468

HIV-1 Virologic Suppression With TMB-365 and TMB-380 Antibodies Study

A Phase 2b Study of the Safety, Pharmacokinetics, and Efficacy of the Combination of TMB-365 and TMB-380 as Maintenance Therapy in HIV-1 Infected Individuals Suppressed With Combination Antiretroviral Therapy

Last checked: Nov 19, 2026Latest source record: Aug 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

88

Actual

Start

Dec 16, 2025

Primary completion

May 2027

Study completion May 2027

Sponsor

Lead sponsor
TaiMed Biologics Inc.Industry
Sponsor type
Industry
First posted
Oct 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

TMB-365 is a monoclonal antibody that binds to the CD4 receptor. TMB-380, aka VRC07-523LS is a monoclonal antibody that binds to HIV. Both interfere with HIV entry. This study is designed to test the combination of the antibodies as maintenance therapy in HIV infected suppressed individuals discontinuing oral cART for 48 weeks. Researchers will compare TMB-365/TMB-380 given IV every 8 weeks to continuation of daily oral cART to see if TMB-365/TMB-380 can also maintain viral suppression. Participants will: 1. Receive TMB-365/TMB-380 infusion or take oral cART as scheduled for 48 weeks 2. Visit the clinic as schedule for checkups and tests

Conditions

  • HIV -1 Infection

Interventions

  • TMB-365Drug

    A monoclonal antibody acts as a HIV post-attachment inhibitor to be given intravenously

  • TMB-380Drug

    A broadly neutralizing antibody (bNAb) against HIV to be given intravenously

  • Baseline ARTDrug

    Baseline ART to be taken daily and orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Antiviral activity of TMB-365 and TMB-380 as maintenance therapy compared to daily oral cARTTime frame: Week 48

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Quest Clinical Research

    San Francisco, California

  • CAN Community Health Fort Lauderdale

    Fort Lauderdale, Florida

  • Midway Immunology and Research Center (MIRC)

    Ft. Pierce, Florida

  • CAN Community Health Miami Gardens

    Miami Gardens, Florida

  • Midland Medical

    Oakland Park, Florida

  • Orlando Immunology Center

    Orlando, Florida

  • CAN Community Health Sarasota

    Sarasota, Florida

  • CAN Community Health Las Vegas

    Las Vegas, Nevada

  • The Rockefeller University

    New York, New York

  • The Crofoot Research Center, Inc.

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.